The backers remained undisclosed.
The company intends to use the funds to advance its BioLexa Platform.
Led by Robb Knie, CEO, Hoth is a development stage biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis, also known as eczema.
FinSMEs
22/02/2018